Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PTHS
SELLPelthos Therapeutics Inc. · Healthcare · United States · $90M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Pelthos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics for infectious diseases and other unmet medical needs. The company's competitive position is anchored by its proprietary drug development platforms and targeted intellectual property portfolio. It operates as a specialized niche player in the biopharmaceutical sector, navigating clinical trials to bring first-in-class treatments to market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.8M | — | 27.7M | 63.9M | 121.2M | 168.6% |
| EPS | -0.44 | -2.12 | -2.51 | -23.04 | — | -22.92 | — | — | — |
| Shares | 3.5M | 3.5M | 3.5M | 3.2M | -6.9% | 3.5M | — | — | — |
| Debt | 0.5M | 1.3M | 2.2M | 34.8M | 300.9% | 52.9M | — | — | — |
| Equity | -3.7M | -6.4M | -2.7M | 38.9M | — | — | — | — | — |
| Op CF | -1.6M | -1.0M | -5.8M | -22.6M | — | -35.1M | — | — | — |
| Inv CF | — | — | 0 | -5.2M | — | — | — | — | — |
| Fin CF | 1.6M | 1.0M | 6.2M | 45.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PTHS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PTHS | Pelthos Therapeutics Inc.(you) | $90M | 24 | SELL |
| PMVP | PMV Pharmaceuticals, Inc. | $66M | 25 | SELL |
| ACET | Adicet Bio, Inc. | $73M | 21 | SELL |
| VRCA | Verrica Pharmaceuticals Inc. | $86M | 16 | STRONG SELL |
| ATRA | Atara Biotherapeutics, Inc. | $71M | 29 | SELL |
| XBIT | XBiotech Inc. | $69M | 29 | SELL |
| NRXS | NeurAxis, Inc. | $84M | 33 | SELL |
| BDTX | Black Diamond Therapeutics, Inc. | $101M | 16 | STRONG SELL |
| RLYB | Rallybio Corporation | $87M | 34 | SELL |
| HURA | TuHURA Biosciences, Inc. | $134M | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%